LRP

Fisheries and Oceans Canada: Recover Capelin and Northern Cod by Pausing the Commercial Capelin Fishery

Retrieved on: 
木曜日, 4月 4, 2024
DFO, NAFO, Health, First Nations, Culture, Whale, Indigenous peoples, Science, Federation, Oceanography, LRP, Abacus Data, History, Capelin, News, Food, Fishery, Plastic, Water, Ecosystem, Biomass, Whaling

They are also important for local food consumption and culture including the annual capelin roll spectacle.”

Key Points: 
  • They are also important for local food consumption and culture including the annual capelin roll spectacle.”
    Connection to Cod: The economic viability of a future cod fishery depends on recovering capelin as a source of food.
  • In DFO’s recent northern cod science assessment, the availability of capelin was identified as the single biggest factor impeding its recovery.
  • Northern cod and capelin populations have stabilized at low levels since 2017, meaning that more capelin is needed for cod to grow.
  • By restoring Canada’s oceans, we can strengthen our communities, reap greater economic and nutritional benefits and protect our future.

Glenn Chamandy sets the record straight on the Gildan Board's poor governance, misrepresentations to stakeholders and obsession with self-entrenchment

Retrieved on: 
水曜日, 1月 24, 2024
Family, Proxy, Employment, LRP, LP, GSG, Chairperson, Trust, History, Cyclone, Strategic planning, Risk, Defamation, Acquisition, COVID-19, Loss, Logbook, Character, Management

On December 10, 2023, I was terminated without cause by the board of directors of Gildan (the "Board").

Key Points: 
  • On December 10, 2023, I was terminated without cause by the board of directors of Gildan (the "Board").
  • The Board's poor governance, failed shareholder engagement, and obsession with self-entrenchment has been on full display.
  • On October 31, 2023, at the request of the Board, I presented a long-range planning proposal ("LRP") prepared by Gildan's management team.
  • Gildan had just announced an excellent quarter, with excellent meetings with shareholders who were in the blind regarding the Board's plan.

STATEMENT BY GLENN J. CHAMANDY IN RESPONSE TO THE OPEN LETTER TO SHAREHOLDERS ISSUED BY GILDAN ACTIVEWEAR'S BOARD OF DIRECTORS

Retrieved on: 
火曜日, 1月 9, 2024
TSX, LRP, Management

MONTREAL, Jan. 9, 2024 /PRNewswire/ - Glenn J. Chamandy, former President and CEO and co-founder of Gildan Activewear Inc. (TSX: GIL) (NYSE: GIL) ("Gildan" or the "Company"), today issued the following statement in response to the open letter to shareholders issued by the Company's board of directors on January 8, 2024:

Key Points: 
  • MONTREAL, Jan. 9, 2024 /PRNewswire/ - Glenn J. Chamandy, former President and CEO and co-founder of Gildan Activewear Inc. (TSX: GIL) (NYSE: GIL) ("Gildan" or the "Company"), today issued the following statement in response to the open letter to shareholders issued by the Company's board of directors on January 8, 2024:
    I am deeply disappointed by the actions of the Gildan board of directors.
  • The board's self-serving motives, designed to distract from its own recklessness, have led them to lose sight of what is truly important—the best interests of the Company, along with its employees, customers and shareholders.
  • Contrary to what the board claims, the comprehensive long-range plan (LRP) presented on October 30, 2023 showed meaningful organic growth prospects for Gildan over the next five years, and was supported by our management team.
  • The board's unfortunate actions have resulted in a massive loss of shareholder value.

Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024

Retrieved on: 
月曜日, 1月 8, 2024
Sciatica, Kidney, Orange Book, Pain management, Food, Migraine, LRP, Pain, FDA, Gout, CMC, Chronic pain, Injection, Patent, NDA, Health, GMP, Neurology, PALO, Medicare, Letter, PDL, Observation, Paracetamol, Growth, Pharmacy, Medicaid, Safety, Patient, MENA, Therapy, Rheumatology, NDS, Creativity, Acute liver failure, Communication, Pharmaceutical industry

PALO ALTO, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today issued a letter from Jaisim Shah, its Chief Executive Officer and President, to its stockholders highlighting the Company’s accomplishments in 2023 and its forward outlook for 2024.

Key Points: 
  • PALO ALTO, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today issued a letter from Jaisim Shah, its Chief Executive Officer and President, to its stockholders highlighting the Company’s accomplishments in 2023 and its forward outlook for 2024.
  • Dear Scilex Holding Company Stockholders,
    I would like to express my deepest gratitude for your unwavering support, patience, and invaluable feedback throughout the transformative year in 2023.
  • As we continue to navigate the complexities of the pharmaceutical landscape, your role as stockholders in this journey is invaluable.
  • Despite the challenges that remain ahead, we are setting ambitious goals for the Company in 2024, including:
    Expected launch of Gloperba®.

Gildan Activewear Board of Directors Issues Open Letter to Shareholders and Sets Record Straight on Browning West’s Misguided Campaign to Reinstall Former Gildan CEO

Retrieved on: 
月曜日, 1月 8, 2024
Narrative, Fruit of the Loom, Browning, Berkshire Hathaway, Sale, LRP, Houchens Industries, Sportswear, Acquisition, NCAA, Analysis, Legislation, Projection, GIL, Letter, Investment, Loom, TSX, Organization, Exercise, Management

MONTREAL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Gildan Activewear Inc. (GIL: TSX and NYSE) (“Gildan” or “the Company”) today issued an open letter to shareholders.

Key Points: 
  • MONTREAL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Gildan Activewear Inc. (GIL: TSX and NYSE) (“Gildan” or “the Company”) today issued an open letter to shareholders.
  • In response to Browning West’s December 29, 2023 letter articulating its misguided campaign to reinstall Glenn Chamandy as CEO of Gildan Activewear, the Board of Directors is sharing further information on recent events.
  • The Board is unanimous in its conviction that retaining Mr. Chamandy as CEO would have jeopardized the future of Gildan and destroyed shareholder value.
  • The Board was left with no other choice but to remove him as CEO.

Scilex Holding Company Announces Positive Type C Meeting with the FDA and Reaches Agreement on Path Forward to File an NDA for SP-102 (SEMDEXATM) in Lumbosacral Radicular Pain (Sciatica)

Retrieved on: 
木曜日, 11月 2, 2023
Type, FDA, Physical medicine and rehabilitation, Medical Affairs Bureau, Johns Hopkins School of Medicine, Outline of health sciences, Food, Chronic pain, Walter Reed National Military Medical Center, SP-102, Rehabilitation, Physician, Neurology, MD, Injection, Dexamethasone, Psychiatry, PALO, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Uniformed Services University of the Health Sciences, Observation, Senior, Behavioural sciences, File, LRP, Anesthesiology, NDA, Pain, Patient, Pharmaceutical industry, Pain management

The Company has reached agreement with the FDA on the path forward to advance the clinical development of SP-102 and on the requirements to file a New Drug Application (“NDA”).

Key Points: 
  • The Company has reached agreement with the FDA on the path forward to advance the clinical development of SP-102 and on the requirements to file a New Drug Application (“NDA”).
  • Recently, during the Type C meeting with the FDA, the Company received an advisement on expectations and requirements to file the NDA, including clinical and preclinical data.
  • Scilex intends to file the SP-102 NDA utilizing the 505(b)(2) regulatory pathway to reference the currently approved drug, Dexamethasone sodium phosphate injection.
  • SP-102 (SEMDEXATM) is expected to be administered in up to 3 injections during a 6-month observation period.

Argentine Agtech startup 'Cattler' is gaining ground among US beef cattle operators

Retrieved on: 
火曜日, 10月 24, 2023
Insurance, PayPal, Economics, Plug and play, Venture capital, Livestock, Software, EID, Tablet, Magic, Partnership, Farmer, Angel investor, LRP, Animal Health, University, Cattle, University of Nebraska–Lincoln, Agriculture, Automation, Federal College of Animal Health and Production Technology, Vom, Dropbox, Mobile phone, Video game, Animal husbandry, Dairy, Toy

SARATOGA, Calif., Oct. 24, 2023 /PRNewswire/ --

Key Points: 
  • More recently it has begun to partner with other companies in partnerships to offer other products to the farmer through this platform.
  • Cattler Corporation is a US company founded by three argentinians: Ignacio Albornoz , Martín Garbulsky and Ezequiel Conti .
  • Jeff is referring to Cattler , the cattle management app that he uses for his farm.
  • Rinkes signed up with Cattler in late 2022 and has been using it every day since.

LRP, The Loss Run Pros and The Iroquois Group Partner to Help Improve Commercial Insurance Customer Experience

Retrieved on: 
火曜日, 8月 15, 2023
LRP, Insurance, Business, Software, Iroquois

MISSOULA, Mont., Aug. 15, 2023 /PRNewswire/ -- Loss Run Pro, a leading software solution for managing the loss run process, announced that it has partnered with The Iroquois Group®, a national network of independent insurance agencies to bring its software service to their retail agency force.

Key Points: 
  • MISSOULA, Mont., Aug. 15, 2023 /PRNewswire/ -- Loss Run Pro, a leading software solution for managing the loss run process, announced that it has partnered with The Iroquois Group®, a national network of independent insurance agencies to bring its software service to their retail agency force.
  • The relationship between Loss Run Pro and Iroquois is a natural fit because both companies are committed to helping their retail agents grow their commercial books of business.
  • "The LRP tool will fit seamlessly into our members' workflows simplifying the process of obtaining loss run data," said Christian Rebello, regional manager in Iroquois' Midwest region.
  • "We look forward to being a resource for Iroquois members to help them grow their commercial book of business," said Brenden Corr, Director of Business Director at Loss Run Pro.

Teleflex to Acquire Palette Life Sciences

Retrieved on: 
水曜日, 7月 26, 2023
Marketing, TRUS, TFX, Fecal incontinence, LRP, Incidence, Vesicoureteral reflux, Acquisition, Rectum, Patient safety, Urology, Growth, FDA, Health, Hand, NYSE, Prostate cancer, Pharmaceutical industry, Medical imaging, Teleflex

Palette Life Sciences is estimated to generate net sales of approximately $56 million, on a standalone basis, in 2023.

Key Points: 
  • Palette Life Sciences is estimated to generate net sales of approximately $56 million, on a standalone basis, in 2023.
  • “The acquisition of Palette Life Sciences will allow us to incorporate this exciting technology into our Interventional Urology business unit and bring urologists, radiation oncologists, and other specialists more innovative technologies that can positively impact patient care.
  • We believe Palette Life Sciences will be a meaningful contributor to our growth in the coming years.
  • The Palette Life Sciences portfolio also includes Deflux® and Solesta®, which are NASHA based tissue bulking agents designed to treat pediatric vesicoureteral reflux and fecal incontinence, respectively.

Loss Run Pro Partners with One80 Intermediaries

Retrieved on: 
木曜日, 5月 18, 2023
LRP, Insurance, Growth, Software as a service, Partnership, P&C, Face

MISSOULA, Mont., May 18, 2023 /PRNewswire/ -- Loss Run Pro, the leading software solution for managing loss run process, today announced its partnership with One80 Intermediaries to bring its software service to their retail agency force.

Key Points: 
  • MISSOULA, Mont., May 18, 2023 /PRNewswire/ -- Loss Run Pro, the leading software solution for managing loss run process, today announced its partnership with One80 Intermediaries to bring its software service to their retail agency force.
  • Loss Run Pro is the first software-as-a-service (SaaS) solution that enables property and casualty (P&C) insurance carriers to manage their loss runs in one place.
  • "We are thrilled to be working with One80 Intermediaries," said Reghan Brandt, CEO of Loss Run Pro.
  • Loss Run Pro will be a tool that our agents can use to set themselves apart from the competition," he continued.